cyrilzakka/clinical-trials huggingface dataset:
Correlation of Gross Motor Movement, and Balance With Screen Time in Healthy Children

Gross motor function involves large muscle control for activities like walking, running, and sports, and is essential for balance and coordination. Excessive screen time may hinder gross motor development by reducing physical activity, affecting strength and coordination. Structured activities like free play and exercise are key to minimizing these effects. A cross-sectional study will be conducted over 10 months in public and private schools in Lahore. Children aged 7-10 will be included. Screen time will be assessed through demographic data, and gross motor skills evaluated using the TGMD-2. Exclusion criteria: PBS \< 20, TGMD-2 \< 30, recent orthopedic surgery, and MMSE \< 26. Data will be analyzed in SPSS v25 using descriptive statistics and correlation. This study explores the impact of screen time on children's physical development, particularly gross motor skills and balance

This study aims to examine the impact of screen time on gross motor development in school-aged children. Gross motor function, which involves large muscle control for activities such as walking, running, and sports, plays a vital role in developing balance, coordination, and overall physical health. With increased screen use among children, physical activity levels may decrease, potentially affecting their motor development.

A cross-sectional study will be conducted over 10 months in public and private schools across Lahore. The target population includes children aged 7 to 10 years. Screen time exposure will be recorded through demographic questionnaires, and gross motor skills will be assessed using the Test of Gross Motor Development-Second Edition (TGMD-2). Children will be excluded if they have a Pediatric Balance Scale (PBS) score below 20, a TGMD-2 score below 30, recent orthopedic surgery, or a Mini-Mental State Examination (MMSE) score below 26. Data will be analyzed using SPSS version 25 with descriptive statistics and correlation tests. This study seeks to identify how screen time may influence key aspects of children's physical development, particularly focusing on gross motor skills and balance

Eligibility Criteria:
Inclusion Criteria:

* Children between ages 7 to 10 years
* Children with screen time exposure of more than 2 hours per day on a weekday (30,
* Screen time exposure through television, smartphones, tablets, laptops or computers.
* Children with exposure of screen time more than 3 hours on a weekend

Exclusion Criteria:

* Children with Pediatric balance score: below 45.
* Children with TGMD-2 Score: below 30 (less than 10" percentile).
* Children who have had orthopedic surgery within the previous 6 months.
* Cognition Score below 26 on MMSE (Mini-Mental State Examination).
Gastric Cancer Survival Without Chemotherapy

This study is observational study to analyze the actual overall survival of the patients who did not receive adjuvant chemotherapy after curative gastrectomy for gastric cancer.

The investigators developed prediction model for the overall survival of these patients and validated.

Adjuvant chemotherapy (AC) after curative gastrectomy is the standard treatment for patients with locally advanced gastric adenocarcinoma in East Asia; however, for various reasons, some patients do not receive this treatment. The aim of this study was to develop a system that reflects the survival rate of patients without AC. A survival prediction model was developed based on the modified staging system and risk factors for overall survival (OS), which were examined using the Cox proportional hazards regression model. The model was validated for the power of prediction and discrimination, compared with the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition; it was externally validated using an independent dataset. the newly developed survival prediction model improves the accuracy of OS prediction for stage II and III gastric cancer patients without AC after curative gastrectomy.

Eligibility Criteria:
Inclusion Criteria:

* histologically confirmed primary gastric adenocarcinoma
* curative R0 resection with D2 lymph node dissection
* pathologic stage II or III gastric cancer

Exclusion Criteria:

* Patients who received neoadjuvant or AC treatment
* follow-up loss or death within 30 days of surgery
* completion of total gastrectomy
* other malignancy within 5 years before gastrectomy
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease

Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.


Eligibility Criteria:
Inclusion Criteria:

Adults aged over 18 years with the evidence of alcoholic liver disease (ALD) based on a thorough history, physical examination, and laboratory tests and all of the following:

* Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire
* Active alcohol use until 4 weeks prior to presentation
* ALT and AST elevated \>1.5 times the upper limit of normal
* Over 1.5 ratio of AST to ALT
* Maddrey Discriminant function(DF) less than 30

Exclusion Criteria:

* Severe alcoholic hepatitis with cirrhosis or life expectancy less than 3 months
* Severe renal impairment (Glomerular filtration rate below 60 ml/min per 1.73m2)
* Hepatic disorders due to cardiac causes, inherited metabolic causes, hemochromatosis and Wilson's disease
* Participants with active viral hepatitis
* Under going active treatment for alcohol withdrawal syndrome(AWS) at the study entry
* Participants on hepatotoxic medications like antitubercular medication, antiviral medication, paracetamol etc.
* Pregnant, attempting to conceive, or lactating women
* Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery

The investigators conducted a controlled, prospective randomized study to examine the antiseptic efficacy of intraoperative irrigation methods during nail avulsion surgery.

The investigators conducted a controlled, prospective randomized study to examine the antiseptic efficacy of intraoperative scrubbing methods during nail avulsion surgery. The investigators compared intraoperative antiseptic scrubbing using 0.9% saline solution and 0.1% polihexanide. Swab samples were taken from each patient at 5 distinct stages throughout the surgical procedure, and bacterial culture analysis was performed (positive culture rate, total inocula count, reduction of bacterial load, and identification of specific microorganisms).

Eligibility Criteria:
Inclusion Criteria:

* Older than 18
* Onychocryptosis

Exclusion Criteria:

* infection
* a history of tinea pedis
* onychomycosis
* paronychia
* nail trauma or subungual hematoma
* nail deformities and disorders
* peripheral vascular disease or diabetes
* cardiac disease
* a history of rheumatic fever
* recent antibiotic use or current antimicrobial therapy
* a history of steroid use and
* recent nail polish use
Infants With Agenesis of the Corpus Callosum

The purpose of this study is to assess the neurological development at three years of age of children born after prenatal diagnosis of "isolated" agenesis of the corpus callosum.

Agenesis of the corpus callosum is the most frequent brain malformation. This anomaly may be diagnosed by ultrasound screening. In half of these prenatal cases, the anomaly seems to be isolated. In this setting, there are no prospective data concerning the development of these children, preventing any clear information to be delivered to parents. Prenatal diagnostic centers therefore face extremely variable rates of termination of pregnancies (TOP), which can reach up to 80%.

This is a multicentric prospective interventional study whose primary objective is to assess the neurological development at three years of age of children born after prenatal diagnosis of "isolated" agenesis of the corpus callosum.

Evaluation at three years will include Intellectual Quotient (IQ) quantification using the WPPSI-III, 3rd edition of Wechsler Preschool and Primary Scale of Intelligence and evaluation of intra-hemispheric coordination using the Vineland adaptative behaviour scale.

Secondary objectives will include:

* Circumstances leading to the prenatal diagnosis of agenesis of the corpus callosum
* Causes leading to termination of pregnancies
* Determination of criteria allowing to confirm that agenesis of the corpus callosum is isolated (family history, imagery, genetics)

These results could allow to determine the optimal prenatal management of such cases.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women from 28 weeks of gestation
* Complete agenesis of the corpus callosum
* Partial agenesis of the corpus callosum
* Abnormal corpus callosum (size, anatomy) As diagnosed by an expert ultrasound fetal brain examination.

Exclusion Criteria:

* age \< 18 years old
* women who do not understand french
* women not covered by the French social security system
* refusal to participate
Pharmacokinetics of Miltefosine in Children and Adults

The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. The results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance.

An open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. The participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/Kg of weight for 28 days.

Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively. Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment.

A population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of Leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. The relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling.

Eligibility Criteria:
Inclusion Criteria:

* Age: 2-12 years of age, or 18-60 years of age
* Weight greater than 10 kg
* Parasitologic confirmation of cutaneous leishmaniasis
* Normal hepatic and kidney function

Exclusion Criteria:

* Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.
* Use of drugs with antileishmanial potential during the previous 6 months, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine
* Mucocutaneous or visceral leishmaniasis
* For female children, menses or other evidence of reproductive maturity
Oral Manifestation in Patients With SARS-CoV2 Infection.

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a "biological barometer" of both viral infection and viral immunosuppression advancement .

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection .

Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of SARS-CoV2 with PCR.
* Age range from 18-60 years old

Exclusion Criteria:

* Pregnancy or contraceptive pills
* Lactation
* Any auto-immune disease that could affect the oral mucosa
* On any neoplastic therapy.
* Uncontrolled diabetes
Comparison of CAMBRA123 and AAPD (CAT) for Caries Risk in Egyptian Children

This study goal is to compare two indices in Egyptian children aged 3-6 years in caries detection and time needed for assessment which will contribute to variable data for pediatric oral health assessment locally and globally.

This study will ensure that patients receive precise evaluations and guide early, appropriate preventive measures or treatments. Over time, this will contribute to reducing caries progression and related complications. Also, Parents become more aware of their children's dental health status, emphasizing the importance of early detection and intervention. Furthermore, Comparing the indices will provide insights into which tool is most efficient and reliable for detecting caries in children 3-6 years old.

Eligibility Criteria:
Inclusion Criteria:

* Children aged 3 to 6 years.
* Both genders.
* No underlying medical conditions affecting oral health.

Exclusion Criteria:

* Uncooperative patient.
* Children with cognitive impairments that prevent understanding the study procedures.
* Parents refused.
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib compared with HAIC of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)


Eligibility Criteria:
Inclusion Criteria:

* The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
* Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.
* Barcelona clinic liver cancer-stage C
* Eastern Cooperative Oncology Group performance status of 0 to 2
* with no previous treatment
* No Cirrhosis or cirrhotic status of Child-Pugh class A only
* Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
* The following laboratory parameters:

Platelet count ≥ 75,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3

• Ability to understand the protocol and to agree to and sign a written informed consent document

Exclusion Criteria:

* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
* Known history of HIV
* History of organ allograft
* Known or suspected allergy to the investigational agents or any agent given in association with this trial.
* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
* Evidence of bleeding diathesis.
* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
* Known central nervous system tumors including metastatic brain disease
Effect of AI Monitoring Blind Spots of EGD on the Inspection Time and Lesion Dection Rate

The goal of this clinic trial is to learn about the effect of AI monitoring blind spots on the inspection time to EGD. Patients are randomly assigned to undergo an EGD with or without the assistance of AI. In the AI group, except for the original videos, there is additional information presented to endoscopists:(1)the virtual stomach model monitoring;(2)time;(3)scoring. Researchers will compare intervention group to see if it have a shorter inspection time compared with the control group.

The goal of this clinic trial is to evaluate the effect of real-time artificial intelligence for monitoring blind spots on the inspection time of EGD. Patients are randomly assigned to undergo an EGD with or without the assistance of AI. In the AI group, except for the original videos, there is additional information presented to endoscopists:(1)the virtual stomach model monitoring;(2)time;(3)scoring. Researchers will compare intervention group to see if it have a shorter inspection time in the case of non-inferior detection rate of gastric neoplastic lesions.

Eligibility Criteria:
Inclusion Criteria:

1. patients aged 18 years or older
2. patients able to give informed consent
3. American Society of Anesthesiology risk class 1,2 or 3

Exclusion Criteria:

1. patients with absolute contraindications to EGD examination
2. patients with a history of previous gastrectomy
3. patients with a serious underlying disease
4. pregnant patients
5. researchers believe that the patient is not suitable to participate in the trial
Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections

there is no yet agreement about the best way to treat Diabetic Macular Edema (DME) the two options up to day are using Grid laser treatment Vs. Avastin injections or a combination of both in this study we want to compare the two attitudes.


Eligibility Criteria:
Inclusion Criteria:

* Diabetic patients with macular edema
* age 30 to 80 Yrs. old
* no previous ocular treatment
* patiens with macular edema that was shown by OCT or FA
* patients with at least 6 months follow-up after the last treatment

Exclusion Criteria:

* patients with other ocular disease (such as glaucoma etc.)
* patients with previous ocular surgery
* patiens with eye trauma
* patiens with macular edema not from DM
The Differences Between Gonadal and Extra-gonadal Malignant Teratomas

A tumor comprising of different types of tissues (such as hair, muscle, bone, etc.) is known as a teratoma. It is a type of germ cell (cells that make sperm or eggs) tumor. When these germ cells have rapid cancerous growth, then such a teratoma is called a malignant teratoma. We have studied the differences between gonadal and extra-gonadal malignant teratomas and the effects of chemotherapy in both genders.

Methods: The samples of 3799 male and 1832 female patients with malignant teratoma samples, between the ages of 1 and 85+ years, were selected from the years 1973 to 2014. Trends in incidence, estimated prevalence, incidence rates, and frequency were calculated in gonadal and extra-gonadal tumors with age adjustment. The fiveyear observed, expected, and relative survival rates were analyzed to study the prognosis.


Eligibility Criteria:
The registry used in our study was the SEER 9 registries Custom Data (with additional treatment fields), Nov 2016 Submission (1973-2014) \< Katrina/Rita Population Adjustment\> - Linked to County Attributes -Total United States, 1969-2015 Counties, National Cancer Institute, DCCPS (Division of Cancer Control and Population Sciences), Surveillance Research Program, released April 2017, based on the November 2016 submission.
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

The objective of this study is to show that thalidomide at a dose of 100 mg/d (with remedial treatment with dexamethasone if a progression occurs) is equivalent in terms of efficacy with thalidomide at 400 mg/d (with remedial treatment with dexamethasone if a progression occurs) in the treatment of refractory or relapsed multiple myeloma after at least two courses of treatment. The use of thalidomide at 100 mg/d should reduce the side effects and improve the safety of the treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patient over 18 years who has been informed about the potential risks and side effects of the treatment and having signed an informed consent to take part in the various aspects of the study.
* Having a refractory or relapsed multiple myeloma after at least two courses of treatment.
* The patients with a refractory or relapsed multiple myeloma after a single course of treatment that included an alkylating drug, can be included if there is no alternative treatment.
* Concerning the thalidomide: Agreement to use and introduction of effective contraception by all the patients:

  1. For women of childbearing potential

     * Oral estroprogestogen contraception introduced at least 1 month before the first administration of thalidomide, and continued until the first menstruation following the end of the treatment, and their partners use a condom.
     * Qualitative serum test for beta-HCG negative: to be done on Day 2 or 3 of the menstrual cycle just before the 1st prescription of thalidomide; in a context of spaniomenorrhea or amenorrhea the test should be done within 3 days after the 1st prescription of thalidomide.
  2. For post-menopausal women

     * 1st situation: Known sterility due to:

       * total hysterectomy;
       * total ovariectomy;
       * total salpingectomy
     * 2nd situation: Natural menopause

       * amenorrhea for at least 1 year and
       * negative progestagen test and
       * plasma FSH \> 50 IU/l
  3. For men: Throughout the duration of the treatment and for 3 months after the end of the protocol (i.e. one spermatogenesis cycle), sexual intercourse must always be protected by using a condom.

Exclusion Criteria:

* Pregnant or breast-feeding women or those of childbearing potential who are not using an effective method of contraception or the lack of protection during sexual intercourse in men.
* Patients who have already received treatment with thalidomide.
* Contraindication to thalidomide.
* Patient who has an absolute contraindication to dexamethasone.
* Patient with a history of deep vein thrombosis and who is not taking effective oral anticoagulation (the anticoagulant must be continued throughout the entire study).
* Performance index more than or equal to 3, unless the patient is bedridden as a result of the progress of the myeloma.
* Any situations that do not permit adequate follow-up of the study.